Relypsa, Inc. Reports the Presentation of its Two-Part Pivotal Phase 3 Patiromer Trial in American Society of Nephrology Late-Breaker Poster

Published: Nov 11, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a clinical-stage biopharmaceutical company, today in a late-breaker poster presentation at the ASN Kidney Week 2013 Annual Meeting in Atlanta, GA, presented additional data in support of the company’s earlier disclosure of statistically significant topline efficacy results in both Part A and Part B of its two-part pivotal Phase 3 clinical trial evaluating patiromer for the treatment of hyperkalemia. According to the poster’s authors, patiromer provided effective serum potassium control with a well-tolerated safety profile that may allow continuous management of serum potassium in hyperkalemic patients, including those with chronic kidney disease (CKD), heart failure and type 2 diabetes, on concurrent renin angiotensin aldosterone system (RAAS) inhibitor therapy.

Help employers find you! Check out all the jobs and post your resume.

Back to news